HBT-708
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 12, 2025
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Solid Tumor
1 to 1
Of
1
Go to page
1